22
Mar
GSK Announces Major Price Cuts for Key Drugs Advair, Valtrex, Lamictal in the US
GlaxoSmithKline (GSK) is set to lower the prices of three significant medications in the US by 2024. This decision impacts Advair, Valtrex, and Lamictal, aiming to enhance drug affordability and comply with the American Rescue Plan Act of 2021's regulatory requirements.
Read More
0
Comments
